ArticleJGH open : an open access journal of gastroenterology and hepatology2026
Vonoprazan-Containing Triple Therapy Based on Clarithromycin Susceptibility May Be Definitive Treatment Strategy for Eradication of
Article in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in Eradication Regimens for Clarithromycin-ResistantPathogens (Basel, Switzerland) · 2026Pooled it
- Vonoprazan-Containing Triple Therapy Based on Clarithromycin Susceptibility May Be Definitive Treatment Strategy for Eradication ofJGH open : an open access journal of gastroenterology and hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Methods: Of 2920 patients who underwent Results: Both the VAC and VAM therapy groups were equivalent in terms of patient backgrounds. The VAM therapy-associated eradication rate of CAM-resistant strains was higher than the VAC therapy-associated eradication rates of both CAM-resistant and CAM-sensitive strains ( Conclusions: Based on CAM susceptibility, VPZ-based triple therapy, VAM, afforded a high eradication rate of CAM-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.